Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction

Juntendo University

Status: Completed

Conditions: Schizophrenia Relapse

Treatments: Drug: reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine

Study type: Interventional

Funder types: Other

Identifiers

NCT03019887

673

Details and patient eligibility

About

To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.

Full description

We attempted to reduce the dose of antipsychotics to ≤1000-mg chlorpromazine eq./day. The dose was gradually reduced at a rate of ≤50-mg chlorpromazine eq./week, and the reduction was discontinued if the subjects relapsed. The differences in baseline cognitive function were analyzed between the patients with no relapse and relapse groups.

Enrollment: 139 patients

Sex: All

Ages: 20 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• inpatients with a diagnosis of schizophrenia, and
• those in the chronic phase receiving mean daily antipsychotic doses exceeding 1000-mg chlorpromazine eq./day.

Exclusion criteria

• mental retardation,
• substance abuse or dependence,
• a history of major head trauma,
• serious medical or neurological disorders, or
• depot antipsychotic injections within the previous 3 months and electroconvulsive therapy within the previous 6 months

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

139 participants in 1 patient group

reduction group

Experimental group

Description:

dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week

Treatment:

Drug: reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine